{"data":{"ticker":"JNJ","slug":"johnson-johnson","name":"Johnson & Johnson","exchange":"NYSE","sector":"Healthcare","headquarters":"New Brunswick, New Jersey","ceo":"Joaquin Duato","employees":138200,"website":"https://www.jnj.com","founded":"1886","layers":[{"slug":"ai-healthcare","name":"AI Healthcare"},{"slug":"robotics","name":"Robotics & Automation"}],"exposure":{"score":12,"tier":"Peripheral","rationale":"Johnson & Johnson sells pharmaceuticals and medical devices, developing the Ottava surgical robot and applying AI to drug discovery and medtech analytics. Surgical robotics gives real but small exposure, and the thesis rests on drug and device franchises, not AI."},"quote":{"price":276.22,"change24hPct":1.43,"change7dPct":1.11,"change30dPct":7.7,"change1yPct":51.39,"high52w":278.43,"low52w":182.46,"marketCap":664947261440,"peRatio":41.92,"eps":6.59,"volume24h":2447065297},"nextEarningsDate":"2027-01-26","summary":"Johnson & Johnson is one of the world's largest healthcare companies. It makes money from pharmaceuticals and medical devices, selling treatments and surgical products to health systems and patients worldwide.","explainer":["Johnson & Johnson is one of the world's largest healthcare companies. It makes money from pharmaceuticals and medical devices, selling treatments and surgical products to health systems and patients worldwide.","Its AI efforts run through both arms. AI drug discovery tools support its pharmaceutical pipeline, surgical robotics AI underpins its medtech ambitions, MedTech AI analytics improve device performance, and clinical trial AI helps design and run studies.","Founded in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson trades on the NYSE and employs about 138,200 people."],"buildoutRole":"Johnson & Johnson sits in the AI Healthcare and Robotics & Automation layers of the AI buildout. Its surgical robotics program, including the Ottava robot in development, gives it real exposure to AI-assisted surgery, and it applies AI to drug discovery, clinical trials, and medtech analytics. That exposure is small relative to the whole: the thesis rests on pharmaceutical and device franchises whose demand has nothing to do with the buildout. AI is a capability inside a healthcare giant.","faq":[{"q":"What does Johnson & Johnson do?","a":"Johnson & Johnson sells pharmaceuticals and medical devices worldwide. It applies AI to drug discovery, clinical trials, and medtech analytics, and is developing the Ottava surgical robot."},{"q":"How is Johnson & Johnson exposed to AI?","a":"Modestly. Surgical robotics and AI drug discovery give real but small exposure inside a business driven by drug and device franchises. Supercycle rates it an AI Exposure Score of 12 out of 100."},{"q":"What are Johnson & Johnson's main AI efforts?","a":"AI drug discovery for its pharmaceutical pipeline, surgical robotics AI including the Ottava program, MedTech AI analytics for devices, and clinical trial AI for study design."},{"q":"Is JNJ a pure play AI stock?","a":"No. Johnson & Johnson is a diversified healthcare company where AI supports the pipeline and devices rather than driving demand. Its AI Exposure Score of 12 out of 100 reflects that."},{"q":"Where is Johnson & Johnson based and who leads it?","a":"Johnson & Johnson is headquartered in New Brunswick, New Jersey, and is led by CEO Joaquin Duato. The company was founded in 1886 and employs about 138,200 people."}],"history1y":[{"date":"2026-09-28","close":271.95},{"date":"2026-09-29","close":267.57},{"date":"2026-09-30","close":264.74},{"date":"2026-10-01","close":258.66},{"date":"2026-10-02","close":256.03},{"date":"2026-10-05","close":252.93},{"date":"2026-10-06","close":254.78},{"date":"2026-10-07","close":258.45},{"date":"2026-10-08","close":256.48},{"date":"2026-10-09","close":261.44},{"date":"2026-10-12","close":263.73},{"date":"2026-10-13","close":248.61},{"date":"2026-10-14","close":253.91},{"date":"2026-10-15","close":253.28},{"date":"2026-10-16","close":255.56},{"date":"2026-10-19","close":253.79},{"date":"2026-10-20","close":259.36},{"date":"2026-10-21","close":257.78},{"date":"2026-10-22","close":267.61},{"date":"2026-10-23","close":263.81},{"date":"2026-10-26","close":266.3},{"date":"2026-10-27","close":268.73},{"date":"2026-10-28","close":271.04},{"date":"2026-10-29","close":275.2},{"date":"2026-10-30","close":273.2},{"date":"2026-11-02","close":270.56},{"date":"2026-11-03","close":266.17},{"date":"2026-11-04","close":276.32},{"date":"2026-11-05","close":272.32},{"date":"2026-11-06","close":276.22}],"incomeStatements":[{"ticker":"JNJ","report_period":"2025-12-31","fiscal_period":"2025-FY","period":"annual","currency":"USD","revenue":94193000000,"cost_of_revenue":30256000000,"gross_profit":63937000000,"operating_expense":0,"operating_income":25596000000,"net_income":26804000000,"earnings_per_share":11.03,"earnings_per_share_diluted":11.03,"research_and_development":14665000000,"selling_general_and_administrative_expenses":23676000000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"JNJ","report_period":"2024-12-31","fiscal_period":"2024-FY","period":"annual","currency":"USD","revenue":88821000000,"cost_of_revenue":27471000000,"gross_profit":61350000000,"operating_expense":0,"operating_income":21249000000,"net_income":14066000000,"earnings_per_share":5.79,"earnings_per_share_diluted":5.79,"research_and_development":17232000000,"selling_general_and_administrative_expenses":22869000000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"JNJ","report_period":"2023-12-31","fiscal_period":"2023-FY","period":"annual","currency":"USD","revenue":85159000000,"cost_of_revenue":26553000000,"gross_profit":58606000000,"operating_expense":0,"operating_income":22009000000,"net_income":35153000000,"earnings_per_share":13.72,"earnings_per_share_diluted":13.72,"research_and_development":15085000000,"selling_general_and_administrative_expenses":21512000000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"JNJ","report_period":"2022-12-31","fiscal_period":"2022-FY","period":"annual","currency":"USD","revenue":79990000000,"cost_of_revenue":24596000000,"gross_profit":55394000000,"operating_expense":0,"operating_income":21013000000,"net_income":17941000000,"earnings_per_share":6.73,"earnings_per_share_diluted":6.73,"research_and_development":14135000000,"selling_general_and_administrative_expenses":20246000000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0}],"balanceSheets":[{"ticker":"JNJ","report_period":"2025-12-31","fiscal_period":"2025-FY","period":"annual","currency":"USD","total_assets":199210000000,"current_assets":55624000000,"cash_and_equivalents":19709000000,"total_liabilities":117666000000,"current_liabilities":54126000000,"total_debt":47933000000,"shareholders_equity":81544000000,"retained_earnings":0},{"ticker":"JNJ","report_period":"2024-12-31","fiscal_period":"2024-FY","period":"annual","currency":"USD","total_assets":180104000000,"current_assets":55893000000,"cash_and_equivalents":24105000000,"total_liabilities":108614000000,"current_liabilities":50321000000,"total_debt":36634000000,"shareholders_equity":71490000000,"retained_earnings":0},{"ticker":"JNJ","report_period":"2023-12-31","fiscal_period":"2023-FY","period":"annual","currency":"USD","total_assets":167558000000,"current_assets":53495000000,"cash_and_equivalents":21859000000,"total_liabilities":98784000000,"current_liabilities":46282000000,"total_debt":29332000000,"shareholders_equity":68774000000,"retained_earnings":153843000000},{"ticker":"JNJ","report_period":"2022-12-31","fiscal_period":"2022-FY","period":"annual","currency":"USD","total_assets":187378000000,"current_assets":55294000000,"cash_and_equivalents":12889000000,"total_liabilities":110574000000,"current_liabilities":55802000000,"total_debt":39642000000,"shareholders_equity":76804000000,"retained_earnings":128345000000}],"holders13f":[{"slug":"ray-dalio","personName":"Ray Dalio","fundName":"Bridgewater Associates","value":169940216,"portfolioPct":0.006971595534453495,"change":"trimmed","period":"2026-06-30"},{"slug":"george-soros","personName":"George Soros","fundName":"Soros Fund Management","value":8639805,"portfolioPct":0.0011335163386386841,"change":"trimmed","period":"2026-06-30"}],"news":[{"title":"First Therapy for Advanced Head & Neck Cancer in 10 Years: Johnson & Johnson Secures Accelerated FDA Nod","source":null,"url":"https://finance.yahoo.com/healthcare/articles/first-therapy-advanced-head-neck-163750896.html?.tsrc=rss","date":"2026-11-06"},{"title":"JNJ's Innovative Medicine Unit Grows in Q3 Despite Patent Losses","source":null,"url":"https://finance.yahoo.com/healthcare/articles/jnjs-innovative-medicine-unit-grows-160400384.html?.tsrc=rss","date":"2026-11-06"},{"title":"Johnson & Johnson (JNJ) Wins FDA Nod For First Dual Targeted Head And Neck Therapy","source":null,"url":"https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-wins-fda-151542174.html?.tsrc=rss","date":"2026-11-06"},{"title":"Is Eli Lilly Stock Worth More Than Its Competitors?","source":null,"url":"https://www.trefis.com/stock/lly/articles/623236/is-eli-lilly-stock-worth-more-than-its-competitors/2026-11-06?.tsrc=rss","date":"2026-11-06"},{"title":"4 Dividend Raisers With Balance Sheets Strong Enough to Keep Raising Through Any Downturn","source":null,"url":"https://247wallst.com/investing/2026/11/06/4-dividend-raisers-with-balance-sheets-strong-enough-to-keep-raising-through-any-downturn/?.tsrc=rss","date":"2026-11-06"},{"title":"5 High-Yield Dividend Stocks That Could Hold Up When the Market Falls","source":null,"url":"https://247wallst.com/investing/2026/11/06/5-high-yield-dividend-stocks-that-could-hold-up-when-the-market-falls/?.tsrc=rss","date":"2026-11-06"},{"title":"State Street Health Care SPDR (XLV) Adds Eli Lilly and J&J on Nov. 4","source":null,"url":"https://finance.yahoo.com/healthcare/articles/state-street-health-care-spdr-110533851.html?.tsrc=rss","date":"2026-11-06"},{"title":"Johnson & Johnson wins FDA approval for Rybrevant cancer treatment","source":null,"url":"https://finance.yahoo.com/healthcare/articles/johnson-johnson-wins-fda-approval-024717396.html?.tsrc=rss","date":"2026-11-06"}]},"meta":{"version":"v1","asOf":"2026-11-06","builtAt":"2026-11-08T15:24:45.397Z","tier":"free","source":"https://supercyclehq.com/stock/johnson-johnson","disclaimer":"Informational only, not investment advice. The AI Exposure Score is Supercycle's editorial opinion. Agent portfolios are simulated paper portfolios run by AI.","license":"Free to use and quote with attribution to supercyclehq.com. Do not redistribute as a dataset."},"links":{"self":"https://supercyclehq.com/api/v1/stocks/JNJ","html":"https://supercyclehq.com/stock/johnson-johnson","md":"https://supercyclehq.com/stock/johnson-johnson.md","docs":"https://supercyclehq.com/api/v1/openapi.json"}}